MARKET

TRVN

TRVN

Trevena Inc
NASDAQ
0.2419
+0.0008
+0.33%
Opening 13:32 07/15 EDT
OPEN
0.2388
PREV CLOSE
0.2411
HIGH
0.2497
LOW
0.2315
VOLUME
208.49K
TURNOVER
0
52 WEEK HIGH
1.120
52 WEEK LOW
0.1910
MARKET CAP
4.44M
P/E (TTM)
-0.1493
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TRVN last week (0708-0712)?
Weekly Report · 13h ago
Trevena announces $2M financing and reduction in liabilities
Trevena, Inc. Announces $2M financing and reduction in liabilities. Biopharmaceutical company Trevena announced an amendment to its March 2022 ex-US royalty-based financing with R-Bridge Healthcare Fund. The company previously received $30M in non-dilute funding.
Seeking Alpha · 07/08 14:18
TREVENA INC: EXPECTS A $10 MLN REDUCTION IN LIABILITIES ASSOCIATED WITH ITS EX-US ROYALTY FINANCING
Reuters · 07/08 13:15
Press Release: Trevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection with Existing ex-US Royalty Financing
Dow Jones · 07/08 13:15
Weekly Report: what happened at TRVN last week (0701-0705)?
Weekly Report · 07/08 10:12
Weekly Report: what happened at TRVN last week (0624-0628)?
Weekly Report · 07/01 10:12
Weekly Report: what happened at TRVN last week (0617-0621)?
Weekly Report · 06/24 10:16
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket
Shares of Sarepta Therapeutics, Inc. Rose sharply in today's pre-market trading. The company announced expanded US FDA approval of ELEVIDYS to Duchenne Muscular Dystrophy patients ages 4 and above. Spectaire Holdings Inc. Shares rose 110% to $0.7140.
Benzinga · 06/21 12:22
More
About TRVN
Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of medicines for patients with central nervous system (CNS) disorders. The Company has one approved product in the United States, OLINVYK (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company’s pipeline includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder. TRV045 is a novel, highly selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. TRV734 is a small molecule G-protein biased ligand of the mu opioid receptor (MOR).

Webull offers Trevena Inc stock information, including NASDAQ: TRVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TRVN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TRVN stock methods without spending real money on the virtual paper trading platform.